Messages in Focus Strategic: Navigate transformational innovation

AI, power and resources, and longevity remain important structural growth opportunities. But elevated expectations, financing constraints, supply bottlenecks, and company-specific risks call for disciplined security selection and diversified exposure. Combining the three captures their collective growth potential, while their differing drivers help reduce risk and reliance on any single source of growth.

by Sagar Khandelwal 18 Nov 2026

Artificial intelligence
We expect AI investment to keep rising in 2027, supported by demand for computing capacity, cloud growth, and expanding usage as costs fall.

But future returns remain uncertain. Like every major investment cycle, AI is likely to experience periods of excess capacity, weaker pricing, and doubts about profitability. In parts of the industry, investment is already running ahead of revenue, while financing costs, execution challenges, power shortages, and data center constraints are rising. Slower cloud growth, weaker business adoption, or supply overtaking demand could further undermine confidence.

We think investors should retain AI exposure and prepare for volatility. We favor financially strong hyperscalers with visible monetization and internally funded investment, alongside select leaders in compute, foundry, and semiconductor equipment. Exposure across applications and adopters can reduce reliance on any single part of the AI ecosystem.

Power and resources
AI is competing with electrification, grid modernization, electric vehicles, industrial automation, and the energy transition for power and equipment. In key developed markets, electricity demand, net of efficiency gains, is rising for the first time in decades. We project USD 32tr in global electrical infrastructure spending over the next decade, spanning power generation, grids, storage, and critical minerals.

We think the most attractive potential opportunities from this trend lie where supply-side constraints are tightest, providing strong pricing power and visibility to future revenues. Companies with scarce production capacity, established order books, strong customer relationships, and a track record of delivering complex projects are best positioned, in our view.

The opportunity is substantial and globally diverse. That said, we believe it prudent to be selective at this stage of the investment cycle, focusing on end-markets with favorable economics and suppliers with a competitive moat. We are carefully monitoring potential risks, including rising financing rates, input cost inflation, permitting delays, and the pace of data center construction, but still believe the magnitude and duration of this investment cycle will be greater than the market currently appreciates.

Longevity
We think the “longevity economy” could grow by around 6% a year, reaching USD 8tr by 2030. Aging populations are increasing demand for care, while advances in drug discovery, diagnostics, and medical technology are improving the treatment of obesity, cancer, cardiometabolic disease, and neurological conditions.

Specifically, we think there is room for further growth in the global obesity market and forecast treatment revenues to grow by an average of 12% a year through 2030. Greater manufacturing capacity, lower prices, oral treatments, wider reimbursement, and additional clinical indications should enlarge the market.

Elsewhere, positive clinical trial results across oncology and neurology could create further company-specific opportunities.

From a portfolio perspective, the health care sector provides a different earnings profile from AI infrastructure and other capital-intensive industries. Demand is generally less sensitive to the economic cycle, although individual investments remain exposed to idiosyncratic risks like clinical results, regulation, and patent expiries.

Disclaimer